Source: Virtual Congress 2020 – ALERT: Infection in adults and children
Disease area: Airway diseases, Paediatric lung diseases, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
J. Chalmers (Dundee (Angus), United Kingdom), D. Cipolla (Hayword, United States of America), B. Thompson (Owings Mills, United States of America), A. Davis (Clayton, United States of America), A. O'Donnell (Washington, United States of America), G. Tino (Philadelphia, United States of America), I. Gonda (Hayward, United States of America), C. Haworth (Cambridge, United Kingdom), J. Froehlich (Hayward, United States of America). Late Breaking Abstract - Changes in respiratory symptoms during 48 weeks treatment with ARD-3150 (inhaled liposomal ciprofloxacin) in bronchiectasis: results from the ORBIT-3 and -4 studies. 4136

Member's Comments

No comment yet.

Related content which might interest you: Changes in respiratory symptoms during 48-week treatment with ARD-3150 (inhaled liposomal ciprofloxacin) in bronchiectasis: results from the ORBIT-3 and -4 studies Source: Eur Respir J, 56 (4) 2000110; 10.1183/13993003.00110-2020 Year: 2020 Late Breaking Abstract - Antibiotic treatment in acute exacerbation of COPD: patient outcomes with amoxicillin vs. amoxicillin/clavulanic acid - Data from 38,820 outpatients. Source: International Congress 2019 – Comorbidities galore in respiratory patients Year: 2019 Late Breaking Abstract - Efficacy of oral prednisolone in patients with stable severe eosinophilic asthma (SEA) treated with Mepolizumab Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 Late Breaking Abstract - Effect of adjunctive tobramycin inhalation therapy in the treatment of ventilator-associated pneumonia: findings from the randomized VAPORISE trial Source: International Congress 2019 – Recent developments in intensive care unit medicine Year: 2019 Changes in the properties of sputum in patients with brochiectasis treated with inhaled manitol for 12 days - A pilot study Source: Annual Congress 2003 - Cellular and molecular mechanisms in epithelium injury and repair Year: 2003 Longitudinal performance of the bronchiectasis severity index (BSI) in patients on regular intravenous (IV) antibiotic therapy for bronchiectasis Source: International Congress 2016 – Clinical and microbiological aspects of bronchiectasis and non-tuberculous mycobacterium (NTM) infections Year: 2016 Dual release ciprofloxacin for inhalation (DRCFI) reduces sputum pseudomonas aeruginosa (Pa) density and delays time to infective pulmonary exacerbation in non-cystic fibrosis (CF) bronchiectasis (BE) Source: Annual Congress 2011 - Advances in antibiotic therapy of non-cystic fibrosis bronchiectasis Year: 2011 Increase in health status after 12 days treatment with inhaled mannitol in patients with bronchiectasis Source: Eur Respir J 2003; 22: Suppl. 45, 430s Year: 2003 Patient-reported clinical control and peak-flow: Effects of 30 versus 6 month treatment with inhaled corticosteroids (ICS) with/without long-acting2-agonists (LABA) in moderately severe COPD Source: Annual Congress 2011 - Disease management in specific primary care populations Year: 2011 Late Breaking Abstract - Danirixin (GSK1325756) improves respiratory symptoms and health status in mild to moderate COPD – results of a 1 year first time in patient study Source: International Congress 2017 – Primary care management of respiratory symptoms, allergies, inhalers and adherence Year: 2017 Effect of inhaled steroid therapy on treatment response in hosptalized pneumonia patients: Results from Turkish Thoracic Society database Source: International Congress 2015 – CAP: prognostic factors in frail patients Year: 2015 Late Breaking Abstract - Short 12-month regimen with intravenous linezolid for pre-XDR TB: treatment outcomes and 24 months follow-up results Source: International Congress 2019 – Tuberculosis: treatment and management Year: 2019 Late Breaking Abstract - Blood eosinophil count (EOS) can accurately predict responsiveness to inhaled corticosteroids (ICS) in COPD, but only if measured while patients are not receiving steroids. Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS Year: 2018 Baseline profiles of subjects randomised in RESPIRE 2 trial of ciprofloxacin dry powder for inhalation (DPI) in non-CF bronchiectasis (NCFB) by pathogen and prior exacerbation rate Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations Year: 2016 Response to the combined therapy in COPD patients (pts) with different plasma surfactant protein D (SPD) level Source: International Congress 2014 – COPD markers Year: 2014 Treatment of moderate to severe asthma with ciclesonide: a long-term investigation over 52 weeks Source: Eur Respir J 2002; 20: Suppl. 38, 406s Year: 2002 Adherence with inhaled colistimethate sodium during a 6 month study in patients with non-cystic fibrosis bronchiectasis Source: Annual Congress 2013 –Treating bronchiectasis in respiratory patients Year: 2013 LATE-BREAKING ABSTRACT: Safety and efficacy of inhaled mannitol over 12 months in high-risk patients with non-CF bronchiectasis Source: International Congress 2014 – Latest insights in airway diseases Year: 2014 Late Breaking Abstract - Pharmacokinetics (PK) of nintedanib with add-on pirfenidone in patients with idiopathic pulmonary fibrosis (IPF): results from INJOURNEY Source: International Congress 2017 – Lung fibrosis: basic science Year: 2017 Late Breaking Abstract - Daily physical activity in patients with severe eosinophilic asthma and the effect of anti-IL5 therapy. Source: International Congress 2018 – New pharmacological strategies in airway diseases Year: 2018